32
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Role of Genetic Variations of DNA Damage Response Pathway Genes and Heat-Shock Proteins in Increased Head and Neck Cancer Risk

ORCID Icon, , , , , , , , & ORCID Icon show all
Pages 3519-3535 | Received 27 Jul 2022, Accepted 08 Sep 2022, Published online: 06 Oct 2022

References

  • Akhtar A , HussainI, TalhaMet al. Prevalence and diagnostic of head and neck cancer in Pakistan. Pak. J. Pharm. Sci.29(Suppl. 5), 1839–1846 (2016).
  • Bray F , FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
  • Puram SV , RoccoJW. Molecular aspects of head and neck cancer therapy. Hematol. Oncol. Clin. North Am.29(6), 971–992 (2015).
  • Braakman I , HebertDN. Protein folding in the endoplasmic reticulum. Cold Spring Harb. Perspect. Biol.5(5), a013201 (2013).
  • Huang S , MonaghanJ, ZhongXet al. HSP 90s are required for NLR immune receptor accumulation in Arabidopsis. Plant J.79(3), 427–439 (2014).
  • Kadota Y , ShirasuK. The HSP90 complex of plants. Biochim. Biophys. Acta Mol. Cell Res.1823(3), 689–697 (2012).
  • Kriechbaumer V , Von LöffelholzO, AbellBM. Chaperone receptors: guiding proteins to intracellular compartments. Protoplasma249(1), 21–30 (2012).
  • Macario A , ConwayDe Macario E. Molecular chaperones: multiple functions, pathologies, and potential applications. Front. Biosci.12(1), 2588 (2007).
  • Calderwood SK , KhalequeMA, SawyerDB, CioccaDR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci.31(3), 164–172 (2006).
  • Matsumoto H , WangX, OhnishiT. Binding between wild-type p53 and hsp72 accumulated after UV and γ-ray irradiation. Cancer Lett.92(2), 127–133 (1995).
  • Ciccia A , ElledgeSJ. The DNA damage response: making it safe to play with knives. Mol. Cell40(2), 179–204 (2010).
  • Dai Y , GrantS. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res.16(2), 376–383 (2010).
  • Lecona E , Fernández-CapetilloO. Replication stress and cancer: it takes two to tango. Exp. Cell Res.329(1), 26–34 (2014).
  • Stracker TH , UsuiT, PetriniJH. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair8(9), 1047–1054 (2009).
  • Weber AM , RyanAJ. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther.149, 124–138 (2015).
  • Zhang L , FokJH, DaviesFE. Heat shock proteins in multiple myeloma. Oncotarget5(5), 1132 (2014).
  • Waterman DP , HaberJE, SmolkaMB. Checkpoint responses to DNA double-strand breaks. Annu. Rev. Biochem.89, 103 (2020).
  • Lanz MC , DibitettoD, SmolkaMB. DNA damage kinase signaling: checkpoint and repair at 30 years. EMBO J.38(18), e101801 (2019).
  • Ali K , MahjabeenI, SabirM, MehmoodH, KayaniMA. OGG1 mutations and risk of female breast cancer: meta-analysis and experimental data. Dis. Markers2015 (2015).
  • Mahjabeen I , ChenZ, ZhouX, KayaniMA. Decreased mRNA expression levels of base excision repair (BER) pathway genes is associated with enhanced Ki-67 expression in HNSCC. Med. Oncol.29(5), 3620–3625 (2012).
  • Mazumder D , MitraS, SinghRKet al. Inactivation of CHEK1 and EI24 is associated with the development of invasive cervical carcinoma: clinical and prognostic implications. Int. J. Cancer129(8), 1859–1871 (2011).
  • Guffanti F , FruscioR, RulliE, DamiaG. The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer. Sci. Rep.6(1), 1–8 (2016).
  • Cho S , KimMJ, ChoiYYet al. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer. Lung Cancer73(1), 25–31 (2011).
  • Dhanaraj B , PapannaMK, AdinarayananSet al. Prevalence and risk factors for adult pulmonary tuberculosis in a metropolitan city of South India. PLOS ONE10(4), e0124260 (2015).
  • Bo S , HuiH, LiWet al. Chk1, but not Chk2, is responsible for G2/M phase arrest induced by diallyl disulfide in human gastric cancer BGC823 cells. Food Chem. Toxicol.68, 61–70 (2014).
  • Albiges L , GoubarA, ScottVet al. Chk1 as a new therapeutic target in triple-negative breast cancer. Breast23(3), 250–258 (2014).
  • Fang Z , GongC, YuSet al. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling. Cancer Lett.415, 58–72 (2018).
  • Deng N , ZhouH, FanH, YuanY. Single nucleotide polymorphisms and cancer susceptibility. Oncotarget8(66), 110635 (2017).
  • Albakova Z , ArmeevGA, KanevskiyLM, KovalenkoEI, SapozhnikovAM. HSP70 multi-functionality in cancer. Cells9(3), 587 (2020).
  • Kohler V , AndréassonC. Hsp70-mediated quality control: should I stay or should I go?Biol. Chem.401(11), 1233–1248 (2020).
  • He L , DengT, LuoH-S. Heat shock protein 70 gene polymorphisms and cancer risk: a meta-analysis. Scientific World Journal2014 (2014).
  • Urban JD , BudinskyRA, RowlandsJC. An evaluation of single nucleotide polymorphisms in the human heat shock protein 90 kDa alpha and beta isoforms. Drug Metab. Pharmacokinet.27(2), 268–278 (2012).
  • Hutz JE . Genetic Analysis of the PI3k/AKT/mTOR Signaling Pathway.Washington University, MO, USA (2010).
  • Revathidevi S , MunirajanAK. Akt in cancer: mediator and more. Seminars in Cancer Biology59, 80–91 (2019).
  • Miyata Y , NakamotoH, NeckersL. The therapeutic target Hsp90 and cancer hallmarks. Curr. Pharm. Des.19(3), 347–365 (2013).
  • Tort F , HernandezS, BeaSet al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia19(1), 112–117 (2005).
  • Koniaras K , CuddihyAR, ChristopoulosH, HoggA, O’ConnellMJ. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene20(51), 7453–7463 (2001).
  • Tenzer A , PruschyM. Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. Curr. Med. Chem. Anticancer Agents3(1), 35–46 (2003).
  • Walworth NC . Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr. Opin. Cell Biol.12(6), 697–704 (2000).
  • Zhou B-BS , ElledgeSJ. The DNA damage response: putting checkpoints in perspective. Nature408(6811), 433–439 (2000).
  • Matsuoka S , NakagawaT, MasudaA, HarukiN, ElledgeSJ, TakahashiT. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res.61(14), 5362–5365 (2001).
  • Consortium C-BC . Low-penetrance susceptibility to breast cancer due to CHEK2* 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet.31(1), 55 (2002).
  • Haruki N , SaitoH, TatematsuYet al. Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res.60(17), 4689–4692 (2000).
  • Wu X , DongX, LiuW, ChenJ. Characterization of CHEK2 mutations in prostate cancer. Hum. Mutat.27(8), 742–747 (2006).
  • Lukas C , FalckJ, BartkovaJ, BartekJ, LukasJ. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat. Cell Biol.5(3), 255–260 (2003).
  • Roos WP , KainaB. DNA damage-induced cell death by apoptosis. Trends Mol. Med.12(9), 440–450 (2006).
  • Gorgoulis VG , VassiliouL-VF, KarakaidosPet al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature434(7035), 907–913 (2005).
  • Zhang H , ChenW, DuanC-J, ZhangC-F. Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma. World J. Surg. Oncol.11(1), 1–8 (2013).
  • Scieglinska D , Gogler-PiglowskaA, ButkiewiczDet al. HSPA2 is expressed in human tumors and correlates with clinical features in non-small cell lung carcinoma patients. Anticancer Res.34(6), 2833–2840 (2014).
  • Calderwood SK , MurshidA. Molecular chaperone accumulation in cancer and decrease in Alzheimer’s disease: the potential roles of HSF1. Front. Neurosci.11, 192 (2017).
  • Oksala NK , EkmekçiFG, ÖzsoyEet al. Natural thermal adaptation increases heat shock protein levels and decreases oxidative stress. Redox Biol.3, 25–28 (2014).
  • Dubey A , PrajapatiK, SwamyM, PachauriV. Heat shock proteins: a therapeutic target worth to consider. Vet. World8(1), 46 (2015).
  • Filipczak PT , PiglowskiW, Glowala-KosinskaM, KrawczykZ, ScieglinskaD. HSPA2 overexpression protects V79 fibroblasts against bortezomib-induced apoptosis. Biochem. Cell Biol.90(2), 224–231 (2012).
  • Juhasz K , LippA-M, NimmervollBet al. The complex function of hsp70 in metastatic cancer. Cancers6(1), 42–66 (2013).
  • Mayer M , BukauB. Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci.62(6), 670–684 (2005).
  • Elzakra N , CuiL, LiuT, LiH, HuangJ, HuS. Mass spectrometric analysis of SOX11-binding proteins in head and neck cancer cells demonstrates the interaction of SOX11 and HSP90α. J. Proteome Res.16(11), 3961–3968 (2017).
  • Buffart TE , CarvalhoB, GriekenNCet al. Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. Oncologist17(5), 653–662 (2012).
  • Jarzab M , KowalM, BalWet al. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy. Folia Histochem. Cytobiol.54(4), 202–209 (2016).
  • Tutar Y , ÖzgürA, TutarE, TutarL, PullieroA, IzzottiA. Regulation of oncogenic genes by microRNAs and pseudogenes in human lung cancer. Biomed. Pharmacother.83, 1182–1190 (2016).
  • Wang J , CuiS, ZhangX, WuY, TangH. High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLOS ONE8(4), e62876 (2013).
  • Zoroquiain P , FaingoldD, AlgahmdiSet al. Analysis of HSP90 expression is valuable in the differential diagnosis of ocular surface squamous lesions. Am. J. Clin. Pathol.145(3), 385–392 (2016).
  • Salces-Ortiz J , GonzálezC, Bolado-CarrancioAet al. Ovine HSP90AA1 gene promoter: functional study and epigenetic modifications. Cell Stress Chaperones20(6), 1001–1012 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.